Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pump Clear all
Completed Not applicable Interventional Results available

Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin

NCT03804983
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hybrid Closed Loop (HCL), Control-IQ with MyTDI
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 29, 2026, 9:04 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effects of Combined Spinal Epidurals on Fever During Labor of First-Time Mothers

NCT00802646
View directory record Official record
Conditions
Vaginal Delivery
Interventions
saline, fentanyl/bupivacaine/epinephrine
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 34 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 29, 2026, 9:04 AM EDT
Completed No phase listed Observational

Loop T2D Observational Study

NCT05951569
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Community-Derived Open-Source Automated Insulin Delivery Loop System
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 29, 2026, 9:04 AM EDT
Withdrawn Not applicable Interventional

Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection

NCT01480531
View directory record Official record
Conditions
Aorta Aneurysm, Dissection of Aorta
Interventions
Clevidipine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 29, 2026, 9:04 AM EDT
Terminated Phase 1 Interventional

A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

NCT05324501
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
MTX110, Programmable pump and catheter system
Drug · Device
Lead sponsor
Biodexa Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Not applicable Interventional Results available

The ARIES HeartMate 3 Pump IDE Study

NCT04069156
View directory record Official record
Conditions
Heart Failure
Interventions
LVAD Implant, Aspirin 100mg, Placebo oral tablet
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gastric Acid Suppression and Probiotic Colonization

NCT03327051
View directory record Official record
Conditions
Probiotics
Interventions
Omeprazole, VSL #3, Placebo
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Not applicable Interventional Results available

Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?

NCT00486902
View directory record Official record
Conditions
Ketamine Adverse Reaction, Effects of; Anesthesia, Spinal and Epidural, in Pregnancy, Complication of Labor and/or Delivery
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Phase 1 Interventional

Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

NCT00392756
View directory record Official record
Conditions
Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions
gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Phase 1 Interventional Results available

Evaluating the Benefits of Physiologic Insulin Delivery

NCT04416737
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Ultra-rapid insulin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

NCT00410956
View directory record Official record
Conditions
Liver Cancer
Interventions
bevacizumab, dexamethasone, floxuridine, protein expression analysis, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging
Biological · Drug · Genetic + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 29, 2026, 9:04 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

NCT07172256
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, New Diagnosis Tumor, Locally Advanced
Interventions
CUE-101, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Esketamine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Not applicable Interventional Results available

Transdisciplinary Versus Usual Care for Type1 Diabetes in Adolescence

NCT03557151
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Usual Care, Transdisciplinary Care-In Person & Telehealth
Other · Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Not applicable Interventional

A Dual-center Study Evaluating Clinical Acceptance of a NPWT Wound Care System

NCT04593693
View directory record Official record
Conditions
Diabetic Foot Ulcer, Pressure Injury, Pressure Ulcer, Surgical Wound, Acute Wound, Traumatic Wound, Dehiscence, Edema
Interventions
Invia Motion Endure NPWT system
Device
Lead sponsor
Medela AG
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Augusta, Georgia • Austell, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The EndoGastric Solutions TEMPO Trial

NCT01647958
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
EsophyX System with SerosaFuse fasteners, PPI
Device · Drug
Lead sponsor
EndoGastric Solutions
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 29, 2026, 9:04 AM EDT
Terminated Not applicable Interventional Results available

Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement

NCT02161484
View directory record Official record
Conditions
Osteoarthritis of Hip, Regional Anesthesia, Other Acute Postoperative Pain, Total Hip Arthroplasty, Peripheral Nerve Block, Lumbar Plexus Nerve Block, Parasacaral (Sciatic) Nerve Block
Interventions
Continuous Lumbar Plexus Block, Parasacral Nerve Block, Ropivacine 0.2%, Bupivacaine 0.0625%
Procedure · Drug
Lead sponsor
Rita Merman
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 29, 2026, 9:04 AM EDT
Not listed Not applicable Interventional

WoundVac in Obese Patients Undergoing Lumbar Surgery

NCT03688438
View directory record Official record
Conditions
Obesity, Lumbar Spine Surgery
Interventions
Closed-Incision Negative-Pressure Therapy
Device
Lead sponsor
Norton Leatherman Spine Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Results available

ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management

NCT00638508
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ketorolac, Ketorolac and Ropivacaine
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Not applicable Interventional Results available

USS Virginia Closed-Loop Versus SAP Therapy for Hypoglycemia Reduction in T1D

NCT02302963
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AP System (DiAs or inControl) with USS Virginia, Sensor-Augmented Pump Therapy (placebo)
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus

NCT03193216
View directory record Official record
Conditions
Barretts Esophagus With Dysplasia
Interventions
Alginates
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00978016
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 29, 2026, 9:04 AM EDT
Terminated Not applicable Interventional Results available

Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

NCT00660348
View directory record Official record
Conditions
Pain, Pancreatic Cancer
Interventions
morphine sulfate, Medtronic intrathecal pump
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 29, 2026, 9:04 AM EDT
Completed Phase 1 Interventional Results available

Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia

NCT03718234
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, Hyperplasia, Adrenal Hyperplasia, Congenital Disorders, Adrenocortical Hyperfunction, Disorders of Sex Development, Urogenital Abnormalities, Genetic Diseases, Inborn, Steroid Metabolic Diseases, Inborn, Adrenal Gland Disease, Hydrocortisone
Interventions
Subcutaneous hydrocortisone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
4 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 29, 2026, 9:04 AM EDT